Skip to main content

Clinical Trials Using Oxaliplatin

Review the clinical trials studying oxaliplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 133

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
FOLFIRINOX Chemotherapy Before Surgery in Treating Patients with Non-Metastatic Pancreatic Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
EUS-RFA PANCARDINAL-1 Trial
Status: Active
Location: The University of Texas Health Science Center, Houston, Houston, Texas
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Sequential Neoadjuvant Chemotherapy for the Treatment of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Status: Active
Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Tadalafil in Combination with FLOT Chemotherapy prior to Surgery for the Treatment of Stage I-III Resectable Gastric/Gastroesophageal Junction Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Ivonescimab in Combination with a Standard Chemotherapy Regimen (FOLFOX) for Controlling Disease Progression in Patients with HER2 Negative Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Propranolol in Combination with Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Botensilimab and Balstilimab with Combination Chemotherapy for the Treatment of Patients with Metastatic Microsatellite Stable Colorectal Cancer
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Circulating Tumor DNA to Determine Early Switch From First-Line mFOLFIRINOX to Second-Line Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
NC410 in Combination with Nivolumab and FOLFIRINOX Chemotherapy, with or without Ipilimumab, for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Microsatellite Stable Localized Rectal Cancer before Surgery
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Comparing two Chemotherapy Regimens (NALIRIFOX and mGAP) in the Treatment of Locally Advanced, Unresectable, and Metastatic Pancreatic Adenocarcinoma
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Neratinib in Combination with Chemotherapy, Trastuzumab, Pembrolizumab in Patients with Stage HER2 Overexpressing Stage IV Gastroesophageal Cancers
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Patients with Unresectable, Locally Advance or Metastatic Pancreatic Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
ctDNA-Directed Chemotherapy after Hepatectomy for the Treatment of Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Preoperative Hypofractionated Radiotherapy with FOLFOX for the Treatment of Stage I-III Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: 2 locations
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Propranolol and Chemoradiation Therapy for the Treatment of Patients with Esophageal Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, Clonal Cytopenia of Undetermined Significance and Chronic Myelomonocytic Leukemia
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Onvansertib in Combination with NALIRIFOX for the Treatment of Metastatic Pancreatic Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas